Menu
Cart 0
Atypical Hemolytic Uremic Syndrome (aHUS) Pipeline Analysis 2018

Atypical hemolytic uremic syndrome (aHUS) Pipeline Analysis 2018 – Focusing on Clinical Trials and Results, Drug Profiling, Patents, Collaborations, and Other Recent Developments

  • $2,400.00
  • Publishing Date: February 2018
  • Format: PDF
Sample Request

Acute Kidney Injury (AKI) Pipeline Analysis report covers more than 10 drugs currently in different phases of development. Acute Kidney Injury (AKI) formerly known as Acute Renal Failure (ARF) is caused due to the sudden decrease in the renal or kidney function. This means that the kidney has lost it ability to filter waste and toxins from the body including the dysregulation of extracellular fluid volume. AKI can be classified into intrinsic, pre-renal and post-renal obstructive nephropathy. Out of the three, the intrinsic AKI is considered to be the true kidney disease while the others are the results of other renal diseases leading to intrinsic kidney disease which further lead to a decrease in the glomerular filtration rate (GFR). A severe increase in the serum creatinine levels and urine output is an indication of acute kidney injury apart from GFR fall.

The report provides Acute Kidney Injury (AKI) treatment drugs by company, phases of development including products in early discovery stage and NDA filing, molecule type, route of administration and region. The report will help to evaluate the collaboration, in-licensing and out-licensing opportunities, formulating business development strategies and tracking the activities of the key market players. Epidemiology, major drivers, restraints, and opportunities have been covered to provide an exhaustive picture of the market. The analysis presents in-depth information regarding the development, trends, and industry policies and regulations implemented to offer stakeholders a better understanding of the key factors affecting the overall market environment.

Various databases (for patents and Clinical Trials), studies and data published by industry associations, analyst reports, investor presentations, press releases and journals among others have been taken into consideration while conducting the secondary research.

Market intelligence is presented in the form of analysis, charts, and graphics to help the clients in gaining faster and efficient understanding of the market.

Major industry players profiled as part of the report are Orion Corporation, Baxter, Quark and Sentien Biotechnologies, Inc. and Pharma Group NV among others.

Scope:

  • By Company
  • By Phase
  • By Molecule Type
  • By Region
  • By Route of Administration
1. Introduction
1.1. Research Methodology
1.2. Research Scope
1.2.1. Analysis by Company
1.2.2. Analysis by Phase
1.2.3. By Molecule Type
1.2.4. By region
2. Disease Overview
2.1.1. Introduction
2.1.2. Classification
2.1.3. Symptoms
2.1.4. Causes
2.1.5. Diagnoses
2.1.6. Treatment
2.1.7. Epidemiology
3. Executive Summary
4. Market Dynamics
4.1. Drivers
4.2. Restraints
4.3. Opportunities
5. Pipeline Analysis/Outlook
5.1. Analysis by Company
5.2. Analysis by Phase
5.2.1. Phase of Development
5.2.1.1. Introduction
5.2.1.1.1. Drug Profiling
• Drug Name
• Generic Name
• Synonyms
• Company
• Collaborator
• Route of administration
• Target
• Mechanism of Action
• Technology
• Molecule type
• CAS Number
• Weight
• Chemical Formula
• IUPAC name
• ATC code
5.2.1.1.2. Strategic Developments
5.2.1.1.3. Clinical trials
5.2.1.1.4. Clinical trial results
5.2.1.1.5. Patents
5.2.1.1.6. Technology
5.2.2. Comparative Analysis for Trials by Phase (Pie, Bar graph)
5.3. By Molecule type
5.4. Analysis by Region
6. Company profiling
6.1. Sentien Biotechnologies, Inc.
6.1.1. Introduction
6.1.2. Financials
6.1.3. Products and Services
6.1.4. SWOT
6.2. AM-Pharma
6.2.1. Introduction
6.2.2. Financials
6.2.3. Products and Services
6.2.4. SWOT
6.3. Angion Biomedica Corp.
6.3.1. Introduction
6.3.2. Financials
6.3.3. Products and Services
6.3.4. SWOT
6.4. Thrasos Therapeutics Inc.
6.4.1. Introduction
6.4.2. Financials
6.4.3. Products and Services
6.4.4. SWOT
6.5. Quark
6.5.1. Introduction
6.5.2. Financials
6.5.3. Products and Services
6.5.4. SWOT
6.6. Orion Corporation
6.6.1. Introduction
6.6.2. Financials
6.6.3. Products and Services
6.6.4. SWOT
6.7. AtoxBio
6.7.1. Introduction
6.7.2. Financials
6.7.3. Products and Services
6.7.4. SWOT
6.8. Complexa
6.8.1. Introduction
6.8.2. Financials
6.8.3. Products and Services
6.8.4. SWOT
6.9. NeuroVive Pharmaceutical AB
6.9.1. Introduction
6.9.2. Financials
6.9.3. Products and Services
6.9.4. SWOT
6.10. AlloCure Inc.
6.10.1. Introduction
6.10.2. Financials
6.10.3. Products and Services
6.10.4. SWOT
6.11. LG LIFESCIENCES (Beijing) CO., LTD.
6.11.1. Introduction
6.11.2. Financials
6.11.3. Products and Services
6.11.4. SWOT
6.12. Baxter
6.12.1. Introduction
6.12.2. Financials
6.12.3. Products and Services
6.12.4. SWOT
6.13. Pharming Group NV
6.13.1. Introduction
6.13.2. Financials
6.13.3. Products and Services
6.13.4. SWOT
6.14. SK chemicals
6.14.1. Introduction
6.14.2. Financials
6.14.3. Products and Services
6.14.4. SWOT
6.15. A1M Pharma AB
6.15.1. Introduction
6.15.2. Financials
6.15.3. Products and Services
6.15.4. SWOT
6.16. Alloksys Life Sciences
6.16.1. Introduction
6.16.2. Financials
6.16.3. Products and Services
6.16.4. SWOT
6.17. Arch BioPartners
6.17.1. Introduction
6.17.2. Financials
6.17.3. Products and Services
6.17.4. SWOT
6.18. Cellmid Ltd.
6.18.1. Introduction
6.18.2. Financials
6.18.3. Products and Services
6.18.4. SWOT
6.19. CFM Pharma Holding B.V.
6.19.1. Introduction
6.19.2. Financials
6.19.3. Products and Services
6.19.4. SWOT
6.20. Cypralis
6.20.1. Introduction
6.20.2. Financials
6.20.3. Products and Services
6.20.4. SWOT
6.21. DURECT CORPORATION
6.21.1. Introduction
6.21.2. Financials
6.21.3. Products and Services
6.21.4. SWOT
6.22. Evotec AG
6.22.1. Introduction
6.22.2. Financials
6.22.3. Products and Services
6.22.4. SWOT
6.23. Exponential Biotherapies, Inc.
6.23.1. Introduction
6.23.2. Financials
6.23.3. Products and Services
6.23.4. SWOT
6.24. Kringle Pharma, Inc.
6.24.1. Introduction
6.24.2. Financials
6.24.3. Products and Services
6.24.4. SWOT

6.25. Mitotech, SA
6.25.1. Introduction
6.25.2. Financials
6.25.3. Products and Services
6.25.4. SWOT
6.26. SBI Pharmaceuticals
6.26.1. Introduction
6.26.2. Financials
6.26.3. Products and Services
6.26.4. SWOT
6.27. Silver Creek Pharmaceuticals, Inc.
6.27.1. Introduction
6.27.2. Financials
6.27.3. Products and Services
6.27.4. SWOT
6.28. SPHERIUM BIOMED S.L.
6.28.1. Introduction
6.28.2. Financials
6.28.3. Products and Services
6.28.4. SWOT
6.29. Torrent Pharmaceuticals Ltd.
6.29.1. Introduction
6.29.2. Financials
6.29.3. Products and Services
6.29.4. SWOT
6.30. Stategics, Inc.
6.30.1. Introduction
6.30.2. Financials
6.30.3. Products and Services
6.30.4. SWOT
List of Tables
List of Figures

Related Reports
Back to the top